Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00781417 · ClinicalTrials.gov registry record · NA

Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease

A NA study of Kidney Disease, sponsored by Atlanta VA Medical Center.

Completed
Registry status
NA
Development phase
48
Enrollment target
1
Study location

NCT00781417: Completed NA study of Kidney Disease, sponsored by Atlanta VA Medical Center.

NCT00781417 is a NA study of Kidney Disease that has completed, run by Atlanta VA Medical Center. The registered enrollment target is 48 participants, below the 2,938-participant average among 23 other Kidney Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00781417, a NA study of Kidney Disease, has completed, sponsored by Atlanta VA Medical Center.

COMPLETED
Registry status
NA
Development phase
48 participants
Enrollment target
1
Study location

Study Summary

This study will evaluate whether earlier intervention with vitamin D in stage II/III chronic kidney disease will prevent or delay secondary hyperparathyroidism. Subjects will receive vitamin D or placebo at study entry and will be followed for a period of one year. The hypothesis is that subjects given vitamin D will have lower PTH and higher 25(OH)D after 1 year compared to placebo. Additionally, there will be less subjects who progress into secondary hyperparathyroidism in the vitamin D treated group compared to the placebo treated group.

Conditions Studied

Interventions

  • OTHER Placebo
  • DIETARY_SUPPLEMENT Vitamin D

Study Locations (1)

Georgia

  • Atlanta VAMC - Atlanta

Trial Details

FieldValue
Enrollment Target 48 participants
Start Date 2008-10
Est. Completion 2011-12
Phase NA
Atlanta VA Medical Center

12 total trials

What the finished NCT00781417 record still lists

NCT00781417 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 2,938-participant average among 23 other Kidney Disease trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Kidney Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00781417 reports a single indexed study location in Georgia.

Frequently Asked Questions

What is clinical trial NCT00781417 about?

NCT00781417 is a clinical study titled "Prevention of Secondary Hyperparathyroidism With Vitamin D in Stage II/III Chronic Kidney Disease". This study will evaluate whether earlier intervention with vitamin D in stage II/III chronic kidney disease will prevent or delay secondary hyperparathyroidism. Subjects will receive vitamin D or placebo at study entry and will be followed for a period of one year. The hypothesis is that subjects gi...

What is the current status of trial NCT00781417?

This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2008-10. Estimated completion is 2011-12.

What conditions does trial NCT00781417 study?

This clinical trial studies the following conditions: Kidney Disease.

What interventions are being tested in trial NCT00781417?

The interventions under investigation include: Placebo (OTHER), Vitamin D (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT00781417?

This trial is sponsored by Atlanta VA Medical Center, which has 12 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00781417 being conducted?

This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Kidney Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00781417's enrollment target sits among peer trials

48 15th of 23 higher than 9 of 23 other Kidney Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Kidney Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01765777 · 48 participants · NA

    Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain

  • NCT03073343 · 48 participants · NA

    A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine

  • NCT03431064 · 48 participants

    Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients

  • NCT03514602 · 48 participants · NA

    Maternal Smoking Cessation and Pediatric Obesity Prevention

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00781417, the US trial registry maintained by the National Library of Medicine. NCT00781417 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.